CYP11A1
ENSG00000140459
Target class
Enzyme
Chromosome
15
Approved drugs
3
Clinical candidates (approved and in development)
3
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Other names
- P450SCC
- Target name
- CYP11A1
- Gene name
- Cytochrome P450 family 11 subfamily A member 1
- Gene symbol
- CYP11A1
- Previous gene symbols
- CYP11A
- Protein name
- Cholesterol side-chain cleavage enzyme, mitochondrial (EC 1.14.15.6) (CYPXIA1) (Cholesterol desmolase) (Cytochrome P450 11A1) (Cytochrome P450(scc))
- Gene biotype
- Protein coding
- Gene family
- Cytochrome P450 family 11
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 37
- Highest tissue expression
- 1,056.44
- Tissue specificity (Gini)
- 0.929
- Tissue specificity (tau)
- 0.996
- KEGG gene identifiers
- hsa:1583
- Protein interaction confidence
- 0.867
- Protein interaction partners
- 33
- R-HSA-196108
- R-HSA-211976
- R-HSA-5579026
- End position
- 74367680
- Start position
- 74337746
- Chromosome
- 15
- Strand
- Reverse
- Mitochondrion inner membrane
- Peripheral membrane protein . Note=Localizes to the matrix side of the mitochondrion inner membrane. .
- Tissue specificity (tau)
- 0.996225
- Expression inequality (Gini)
- 0.928691
Expression in transcripts per million
- Adrenal Gland
- 1,056.44
- Ovary
- 68.92
- Testis
- 47.47
- Esophagus - Mucosa
- 8.13
- Spleen
- 6.45
Expression in transcripts per million
- Adrenal Gland1,056.44
- Ovary68.92
- Testis47.47
- Esophagus - Mucosa8.13
- Spleen6.45
- Nerve - Tibial5.72
- Pituitary3.69
- Fallopian Tube3.55
- Uterus3.49
- Cervix - Endocervix3.48
- Brain - Caudate (basal ganglia)3.15
- Breast - Mammary Tissue3.1
- Adipose - Subcutaneous2.84
- Brain - Putamen (basal ganglia)2.77
- Brain - Nucleus accumbens (basal ganglia)2.6
- Adipose - Visceral (Omentum)2.5
- Brain - Anterior cingulate cortex (BA24)2.16
- Brain - Amygdala2.15
- Brain - Cortex2.11
- Liver2.02
- Brain - Substantia nigra1.98
- Cervix - Ectocervix1.96
- Brain - Frontal Cortex (BA9)1.92
- Prostate1.79
- Brain - Hippocampus1.66
And 29 more, listed on the interactive page.
- GO:0006700
- GO:0008203
- GO:0016125
- GO:0120178
- GO:0005739
- GO:0005759
- GO:0005515
- GO:0008386
- GO:0020037
Related records
Trials (38)
- A Phase 1/2a Study of the 2S,4R Enantiomer of Ketoconazole in Subjects With Type 2 Diabetes Mellitus
- A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes
- A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma
- A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer
- A Safety and Feasibility Study of Mitotane in Prostate Cancer
- A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.
- A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.
- Alternation in the Human Microbiome With Commonly Used Topical Medications
- An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's Foot
- Bioavailability of Levoketoconazole and Ketoconazole Tablets
- Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor
- Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis
- Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis
- Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia
- Efficacy of Adjuvant Mitotane Treatment (ADIUVO)
- Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)
- Hormonal Mechanisms of Sleep Restriction - Axis Study
- Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women
- IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery
- ITT4 Intratesticular Hormonal Milieu in Man (ITT4)
Drugs (3)
- Aminoglutethimide Cytochrome P450 11A1 inhibitor
- Levoketoconazole Cytochrome P450 11A1 inhibitor
- Mitotane Cytochrome P450 11A1 inhibitor